Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allogene Therapeutics Inc ALLO

Healthcare Biotechnology
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a... see more

Recent & Breaking News (NDAQ:ALLO)

Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)

GlobeNewswire August 12, 2021

Allogene Therapeutics Reports Second Quarter 2021 Financial Results

GlobeNewswire August 4, 2021

Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors

GlobeNewswire August 2, 2021

Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021

GlobeNewswire July 27, 2021

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

GlobeNewswire July 12, 2021

Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR(TM) T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma

GlobeNewswire June 30, 2021

Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer

Business Wire June 21, 2021

Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology

GlobeNewswire June 4, 2021

Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

GlobeNewswire May 20, 2021

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

GlobeNewswire May 19, 2021

Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021

GlobeNewswire May 12, 2021

Allogene Therapeutics Reports First Quarter 2021 Financial Results 

GlobeNewswire May 5, 2021

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T(TM) Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

GlobeNewswire April 28, 2021

Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021

GlobeNewswire April 27, 2021

Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T(TM) Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma

GlobeNewswire April 21, 2021

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR(TM) Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

GlobeNewswire April 19, 2021

Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

GlobeNewswire April 12, 2021

Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR(TM) T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting

GlobeNewswire April 10, 2021

Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

GlobeNewswire February 25, 2021

Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

GlobeNewswire February 18, 2021